The business of healthcare innovation / (Registro nro. 17540)
[ vista simple ]
| 000 -CABECERA | |
|---|---|
| Campo de control de longitud fija | 37130cam a22003017a 4500 |
| 001 - NÚMERO DE CONTROL | |
| Campo de control | 17251918 |
| 005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN | |
| Campo de control | 20160624114116.0 |
| 007 - CAMPO FIJO DE DESCRIPCIÓN FÍSICA | |
| DESCRIPCIÓN FÍSICA | ta |
| 008 - CAMPO FIJO DE DESCRIPCIÓN FIJA--INFORMACIÓN GENERAL | |
| Campo de control de longitud fija | 120410s2012 enka b 001 0 eng |
| 020 ## - ISBN (INTERNATIONAL STANDARD BOOK NUMBER) | |
| ISBN | 9781107024977 (hardback) |
| 020 ## - ISBN (INTERNATIONAL STANDARD BOOK NUMBER) | |
| ISBN | 9781107607774 (pbk.) |
| 040 ## - FUENTE DE CATALOGACIÓN | |
| Agencia de catalogación original | DNLM/DLC |
| Agencia que realiza la transcripción | DLC |
| 082 00 - NÚMERO DE LA CLASIFICACIÓN DECIMAL DEWEY | |
| Número de clasificación Decimal | 610.28 |
| Número de edición DEWEY | 23 |
| Número de documento (Cutter) | B979 |
| 245 04 - TÍTULO PROPIAMENTE DICHO | |
| Título | The business of healthcare innovation / |
| Mención de responsabilidad, etc. | edited by Lawton Robert Burns. |
| 250 ## - MENCIÓN DE EDICIÓN | |
| Mención de edición | 2nd ed. |
| 260 ## - PUBLICACIÓN, DISTRIBUCIÓN, ETC (PIE DE IMPRENTA) | |
| Lugar de publicación, distribución, etc. | Cambridge, UK : |
| Nombre del editor, distribuidor, etc. | Cambridge University Press, |
| Fecha de publicación, distribución, etc. | 2012. |
| 300 ## - DESCRIPCIÓN FÍSICA | |
| Extensión | xxiv, 574 p. : |
| Otros detalles físicos | il. ; |
| Dimensiones | 26 cm. |
| 504 ## - NOTA DE BIBLIOGRAFÍA, ETC. | |
| Bibliografía, etc. | Incluye bibliografía e indices |
| 505 ## - NOTA DE CONTENIDO FORMATEADA | |
| Nota de contenido con formato preestablecido | Abbott 19, , 45, 65, 67, 108, 142, 436–437<br/><br/>Abele, John 388<br/><br/>ACO (accountable care organization) 546–547, , 554–555<br/><br/>affordable innovation 529<br/><br/>AHCA (Agency for Health Care Administration) (Florida) 95<br/><br/>alliances, definition of 357<br/><br/>Alzheimer’s 36, 48, 211<br/><br/>AMC (academic medical center) 175, 176<br/><br/>American Recovery and Reinvestment Act (2009) 244<br/><br/>aneurysm treatment 395–396<br/><br/>angel networks 351<br/><br/>anti-stenotic drugs 19<br/><br/>antisense 222–223<br/><br/>API (active pharmaceutical ingredient) 63, , 108–109<br/><br/>arthritis therapies 36<br/><br/>ASC (ambulatory surgery center) 549<br/><br/>assay development 53, 54<br/><br/>Bakken, Earl 388<br/><br/>Bayh–Dole Act (1980) 199<br/><br/>BCG (Boston Consulting Group) 5, 9, 149, 428, 435<br/><br/>Berg, Marc 472–473<br/><br/>beta-interferons 207–208<br/><br/>biogenerics 520<br/><br/>biologicals 34<br/><br/>biomarkers 83<br/><br/>bioproducts 33, 34<br/><br/>biosimilars 308–309, 314, 315–316, 354<br/><br/>biotechnology business/revenue models<br/><br/>and capital markets 349–350<br/><br/>data mining alliances 369–370<br/><br/>definitions 348–349<br/><br/>genomics technology platform companies 363–366<br/><br/>macro/micro factors affecting 353–355<br/><br/>motivators for change 350<br/><br/>proteomic technology platform companies 363–366<br/><br/>specialty drug development model 361<br/><br/>technological reintegration and healthcare value chain 361–366<br/><br/>technology development alliances 370–371<br/><br/>technology platform companies 363–375,<br/><br/>technology transfer alliances 371–372<br/><br/>performance measurement 372–375<br/><br/>productivity measurement 372–373<br/><br/>therapeutic area alliances 368–369<br/><br/>venture capital model 351–352<br/><br/>vertical integration 349–350, 355–361<br/><br/>biotechnology industry 38–39<br/><br/>Asia 285–303, , , , ,<br/><br/>Australia 297–298<br/><br/>Canada 283–285<br/><br/>challenges to industry 346–347<br/><br/>culture of flexibility in management 274<br/><br/>diseases tackled by 205–212<br/><br/>drug discovery/development 520<br/><br/>drug regulation in US 303–319<br/><br/>employment from 211<br/><br/>ethical issues 347<br/><br/>in Europe 276–283, ,<br/><br/>global companies 302–303<br/><br/>global structure of 274–303<br/><br/>impact on healthcare 205–212<br/><br/>innovation gaps 258–260<br/><br/>investment risk 195<br/><br/>managing biotechnology firms 271–274<br/><br/>and merger and acquisition (M&A) 157<br/><br/>merger and acquisition (M&A) trends in 124–130,<br/><br/>molecular diagnostics companies 219<br/><br/>monoclonal antibodies 206, 208, 212–215<br/><br/>and multiple sclerosis 207–208<br/><br/>in multiple technologies 515–516<br/><br/>and national healthcare cost constraints 258<br/><br/>and pharmaceutical companies 126–130, 204–205, 247–269, 328, 352–353<br/><br/>policy 303–326<br/><br/>product validation 251<br/><br/>productivity gaps 258–260<br/><br/>proteomics 2, 219–220<br/><br/>RDD (rational drug design) 20, 220–221,<br/><br/>rDNA (recombinant DNA) 196, 199–201, , 202<br/><br/>regulation 303–326<br/><br/>revenues 517–518<br/><br/>sector innovation 2<br/><br/>as seen by pharmaceutical companies 251<br/><br/>sequencing capability 218–219<br/><br/>and specialty pharmacy providers 173<br/><br/>spread of 199–201,<br/><br/>therapeutics sector 25, 201–205<br/><br/>tool companies 218<br/><br/>United Kingdom 278–280<br/><br/>biotechnology products, major issues 68–69<br/><br/>bioterrorism 318–319<br/><br/>Biotherapeutics and Bioinnovation Center (BBC) 130<br/><br/>BLA (biologics licensing application) 315<br/><br/>blockbuster drugs 119–120, 133, , 137, 258, 273, 555<br/><br/>Blumenthal, David 474<br/><br/>BMP-2 19<br/><br/>Booth, Bruce 246<br/><br/>bottom-up experimentation 8<br/><br/>Boyer, Herbert 196<br/><br/>BPR (business process reengineering) 468–469<br/><br/>brand switching 414<br/><br/>business models 5, 8, 25–26, , 69–73, 520–522<br/><br/>business strategies 6<br/><br/>CABG (coronary artery bypass graft) 12<br/><br/>CAM (complementary and alternative medicine) 549, 550–551<br/><br/>cancer metabolism 224<br/><br/>cancer therapies 36<br/><br/>capability of firms 7<br/><br/>capital, in-house venture capital 527<br/><br/>capital markets and finance 236–247, 264, 349–350, 351–352, 365, 370–371, 440–441, 518<br/><br/>cardiac bypass 12<br/><br/>care accountability 546–547<br/><br/>care delivery 546<br/><br/>COEs (centers of excellence) 549<br/><br/>consumer- and patient-centered care 550–551<br/><br/>decentralization 549–550<br/><br/>implications for suppliers 552–553<br/><br/>mixed payment sources 551–552<br/><br/>care and disease management IT 488–489<br/><br/>CDHP (consumer-directed health plan) 489–490<br/><br/>CDSS (computerized decision-support system) 469<br/><br/>Centers for Therapeutic Innovation 175<br/><br/>CenterWatch 150<br/><br/>CER (comparative effectiveness research) 96, 309, 546, 549, 553,<br/><br/>cGMP (current good manufacturing practice) 62, 67–68,<br/><br/>cGxP (current good practice) 105, 107<br/><br/>Chakrabarty, Ananda 198<br/><br/>China<br/><br/>biotechnology industry 293–296<br/><br/>cGxP (current good practice) 105<br/><br/>drug discovery/development 204<br/><br/>GlaxoSmithKline center of excellence 104<br/><br/>hybrid business models 104<br/><br/>intellectual property rights 103<br/><br/>merger and acquisition (M&A) entry 132<br/><br/>multinationals in 103–105,<br/><br/>National Economic Plans 106<br/><br/>pharmaceutical industry 46, 81<br/><br/>as pharmaceutical market 102–106<br/><br/>political system 106<br/><br/>research and development (R&D) 104<br/><br/>regulation and quality 321<br/><br/>TCM (traditional Chinese medicine) 102, 540<br/><br/>CHINs (community health information networks) 463<br/><br/>CHMP (Committee for Medicinal Products for Human Use) 323<br/><br/>Chorus translational development concept 46–47<br/><br/>claims management IT 483–488, ,<br/><br/>Clark, Richard 262<br/><br/>clinical decision-making 546<br/><br/>clinical development<br/><br/>challenges in 82–85<br/><br/>globalization of 82<br/><br/>clinical genetics 475<br/><br/>clinical needs, economics of 415–417<br/><br/>clinical trials<br/><br/>See research and development<br/><br/>cloud computing 457<br/><br/>CME (continuing medical education) credits 90<br/><br/>CMO (contract manufacturing organization) 121, 136, 552<br/><br/>CMS (Center for Medicare and Medicaid Services) 15<br/><br/>COGS (cost of goods sold) 63, 423–424<br/><br/>Cohen, Stanley 196<br/><br/>Coleman, Alan 310–311<br/><br/>collaboration management 528<br/><br/>collaborative model 26<br/><br/>combinatorial chemistry 221<br/><br/>Comité Économique du Médicament 49<br/><br/>common business model 520–522<br/><br/>COMP (Committee for Orphan Medicinal Products) 323<br/><br/>competitive forces 6<br/><br/>competitive scale 139–140<br/><br/>competitive scope 139–140<br/><br/>compound potency 65–66<br/><br/>computer-based molecular modeling 20<br/><br/>CON (Certificate of Need) laws 3–4, 11<br/><br/>concentration ratios in mergers and acquisitions (M&As) 437–439<br/><br/>conflicts of interest 11<br/><br/>consumer health ecosystem 556<br/><br/>consumer and patient centered care 550–551<br/><br/>consumerism and healthcare 543–544<br/><br/>convergent product 19<br/><br/>convergent thinking 8<br/><br/>convertible debt securities 243<br/><br/>COURAGE trial 396–397<br/><br/>CPOE (computerized physician order entry) 468–475, , ,<br/><br/>Crick, Francis 196<br/><br/>CRM (customer relationship management) 101<br/><br/>CRO (contracted research organization) 121, 136, 225, 235<br/><br/>cross-sector technology 19–21<br/><br/>crystallography 54<br/><br/>CSL (clinical science liaison) 99–100<br/><br/>CSO (contract sales organization) 121, 136<br/><br/>CTD (common technical document) 320<br/><br/>cyclical financing 237<br/><br/>data mining alliances 369–370<br/><br/>de-diversification 122, 166<br/><br/>de-diversifying 527<br/><br/>DEB (drug-eluting balloon) 19<br/><br/>defibrillators 389–391, 392–393, 399–400, 415, 418, 421<br/><br/>demonstration programs 173<br/><br/>DES (drug-eluting stent) 12, 19, 383, 431–432<br/><br/>desperation index 137<br/><br/>Dickey-Wicker Amendment 312<br/><br/>digital radiology 476<br/><br/>disease identification advances 542<br/><br/>disease and pharmaceutical pricing 47–50<br/><br/>disease treatment advances 542<br/><br/>disease trends 51<br/><br/>divergent thinking 8<br/><br/>diversification 33, 44–45, , 122, 131–132, 166, 524, 525–526, 531<br/><br/>DM (disease management) program 95<br/><br/>DMF (drug master file) 321<br/><br/>DNA 38, 196, 217, 221–222<br/><br/>donut hole 309<br/><br/>downstream customers 6<br/><br/>downstream value chains 546<br/><br/>Drews, Jürgen 366<br/><br/>drug delivery devices 533<br/><br/>drug development, scale effects 154–155<br/><br/>drug discovery 204, 220, 366, 367–368, 520<br/><br/>drug fallout 61,<br/><br/>drug insurance tier status 93–94<br/><br/>drug product 62–69,<br/><br/>drug regulation 303–326, , ,<br/><br/>drug substance 62–69,<br/><br/>drug supplies 13, 15–16<br/><br/>drug therapy 533<br/><br/>drug-coated device 33<br/><br/>drug-hunting 46, 165<br/><br/>drug/device collaboration 533<br/><br/>drug/device convergence 431–433<br/><br/>drugs, pay-for-performance 171<br/><br/>DTCA (direct to consumer advertising) 16, 90, 100–101, , 425–426<br/><br/>earnings growth and pipeline problems 136–139<br/><br/>EBM (evidence-based medicine) 546, 547–549<br/><br/>economies of scale 131, 143–145<br/><br/>economies of scope 131, 143–145<br/><br/>EDL (essential drugs list) 106<br/><br/>efficiency, and scale/scope 152–155<br/><br/>EFPIA (European Federation of Pharmaceutical Industries and Associations) 320<br/><br/>EHRs interoperable (electronic health records) 462, 466<br/><br/>electrophysiology 421<br/><br/>EMA (formerly EMEA, or European Agency for the Evaluation of Medicinal Products) (European Medicines Agency) 321–325,<br/><br/>EMR (electronic medical record) 453, 468–470, 482–483<br/><br/>EPI-MEDICS 477–479<br/><br/>epigenetics 224–225<br/><br/>EPO (erythropoietin) 226<br/><br/>ESC (embryonic stem cell) research 309–313<br/><br/>evidence-based care<br/><br/>See EBM<br/><br/>exit options financing 357<br/><br/>Factor Xa therapies 36, 73<br/><br/>FDA (Food and Drug Administration) regulation 9, 56, 59–60, , 62, 67–68, , 74–75, 77, 83, 85–86, 91, 99, 101, 120, 122, 257–258, 308, 314, 320, 381, 384, 441–445, 532, 535<br/><br/>FDA pre-market approval (PMA) 442–443<br/><br/>FDA risk classification system 442–443<br/><br/>FDAMA (Food and Drug Administration Modernization Act 1997) 16, 99<br/><br/>FIDDO (fully integrated drug discovery and development organization) 357<br/><br/>FIH (first in human) starts 119<br/><br/>finance 5, 236–247, 264, 349–350, 351–352, 357, 365, 370–371, 440–441<br/><br/>financial resources 523, 524<br/><br/>FIPCO (fully integrated pharmaceutical company) model 169, 225, 226–228, 236, 357, 360, 517, 520, 537<br/><br/>FIPNet (fully integrated pharmaceutical network) 169<br/><br/>first-cycle approval rates 86<br/><br/>Five Forces framework 6–7<br/><br/>510(k) clearances 445<br/><br/>flexibility, culture of 274<br/><br/>FOB (follow-on biologics) 314–316<br/><br/>form/fill/finish (F/F/F) sites 63–64<br/><br/>Fortune Global 500 firms 23<br/><br/>free-standing care (care delivery decentralization) 549–550<br/><br/>French Anderson, William 208–209<br/><br/>frugal innovation 529<br/><br/>FSS (Federal Supply Schedule) 49<br/><br/>fungibility of resources 523–524<br/><br/>G-CSF (granulocyte-colony stimulating factor) 34<br/><br/>Garnier, Jean-Pierre 263<br/><br/>GCP (good clinical practice) guidelines 326<br/><br/>gene expression 54<br/><br/>gene therapy 208–209, 222<br/><br/>General Electric six-sigma/lean management 16<br/><br/>generic biologics 314–316<br/><br/>generic drug companies 37–38<br/><br/>generic drugs 33<br/><br/>genetics, clinical 475<br/><br/>Genetics Institute 226–228<br/><br/>genomics 2, 215–219, 254, 347, 366, 367–368<br/><br/>genomics technology platform companies 363–366<br/><br/>germline gene therapy 313–314<br/><br/>Gilbert, Walter 232–233<br/><br/>global outsourcing 491<br/><br/>globalization of clinical development 82<br/><br/>GMP (good manufacturing practice) 62<br/><br/>Golub, Todd 219<br/><br/>government grants 243–244<br/><br/>GPO (group purchasing organization) 18, 133–134<br/><br/>GWA (genome-wide association) studies 217<br/><br/>Hammer, Michael 468–469, 473<br/><br/>Hatch-Waxman Act (1984) 16, 125, 133, 136, 314<br/><br/>HDL (high-density lipoprotein) 36<br/><br/>health communities 500–503<br/><br/>Health Security Act 124<br/><br/>health spending benefits 3–4<br/><br/>healthcare<br/><br/>affordability of 543<br/><br/>and consumerism 543–544<br/><br/>technology convergence in 531–534,<br/><br/>training needs 544–546<br/><br/>healthcare courses 1–3, 9–10,<br/><br/>healthcare delivery systems 544–546<br/><br/>healthcare hedge funds 246<br/><br/>healthcare innovation<br/><br/>demographics 540–541<br/><br/>environment 37<br/><br/>expanding scientific/technological bases 541<br/><br/>healthcare intermediaries 1–3<br/><br/>healthcare IT (information technology)<br/><br/>analysis of sector 27<br/><br/>benefits of 454–455<br/><br/>business models 461<br/><br/>care automation 455–458<br/><br/>care and disease management 488–489<br/><br/>CDHP (consumer-directed health plan) 489–490<br/><br/>claims management 483–488, ,<br/><br/>cloud computing 457<br/><br/>consumer demand for healthcare IT 495–496<br/><br/>consumer use of 494–503<br/><br/>in England 464–465<br/><br/>government spending on 462<br/><br/>hardware development 456<br/><br/>health communities 500–503<br/><br/>and hospital management 504<br/><br/>increased connectivity 542–543<br/><br/>innovation in 2<br/><br/>interoperability 462, 467–468<br/><br/>major players 492–494<br/><br/>market structure 458–461<br/><br/>multiple technologies 515–516<br/><br/>national health data access 463–468<br/><br/>personal health records 496–497<br/><br/>PHR (personal health record)<br/><br/>See PHR<br/><br/>RAND report 454–455<br/><br/>remote patient monitoring/management 476, 480–481<br/><br/>scale in US 451–453<br/><br/>slow progress in 453–454<br/><br/>smartcards 463–464<br/><br/>system response 455<br/><br/>systems integration 490–494<br/><br/>in US 466–468<br/><br/>virtual primary care 481–482<br/><br/>healthcare outsourcing 490–494<br/><br/>healthcare producers, study of 9–19<br/><br/>healthcare reform 307–309, 445–447<br/><br/>healthcare value chain 361–366, 544–545, 552<br/><br/>herbs 33<br/><br/>high science 9<br/><br/>high throughput screening 20<br/><br/>HIPAA (Health Insurance Portability and Accountability Act 1996) 466, 475, 483–485<br/><br/>HITECH (Health Information Technology for Economic and Clinical Health) Act 452, 454–455, 467, 474,<br/><br/>HMO (health maintenance organization) 93, 133–134,<br/><br/>horizontal integration 157–158<br/><br/>hospitals<br/><br/>chief executive training 12<br/><br/>healthcare supply costs 11<br/><br/>HSA (health savings account) 489, 551<br/><br/>HTAs (health technology assessments) 96<br/><br/>HTS (high-throughput screening) 54, , 221<br/><br/>human cloning 313–314<br/><br/>human genome mapping/decoding 80, 120<br/><br/>Human Genome Project 215, 365<br/><br/>Human Genome Sciences 254, 368–369<br/><br/>hybrid business models 104<br/><br/>ICH International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use 319, 320–321<br/><br/>imaging 20,<br/><br/>in control, concept of 59, 66<br/><br/>in-house venture capital 527<br/><br/>in-licensing<br/><br/>See licensing<br/><br/>IND (investigational new drug) applications 56, 119<br/><br/>India<br/><br/>animal experiments 107<br/><br/>biotechnology industry 298–300<br/><br/>cGxP 107<br/><br/>drug discovery/development 204<br/><br/>generic pharmaceutical companies 108–109<br/><br/>internal market 106–107<br/><br/>merger and acquisition (M&A) entry 132, 142<br/><br/>multinationals in 107, 108<br/><br/>pharmaceutical industry 46, 81, 106–111<br/><br/>pharmaceutical production levels 108<br/><br/>political system 107<br/><br/>research and development (R&D) 110–111<br/><br/>industry concentration 158<br/><br/>inflammation therapies 36<br/><br/>information asymmetry 161<br/><br/>information-based platform technologies 20<br/><br/>infrastructure costs 134–136<br/><br/>Infuse spine cage 432<br/><br/>innovation 2<br/><br/>affordable innovation 529<br/><br/>ambidextrous firms 528–529<br/><br/>business model 5, 73–87<br/><br/>from generics base 45<br/><br/>from service company base 46<br/><br/>frugal innovation 529<br/><br/>in healthcare business 27–28<br/><br/>medical devices decline 409<br/><br/>and mergers and acquisitions (M&As) 522<br/><br/>negative innovation 529<br/><br/>open source innovation 167<br/><br/>organizational 8–9<br/><br/>pure innovation models 44–45<br/><br/>questions about 5–6<br/><br/>reverse innovation 529<br/><br/>and value chain 1–3<br/><br/>and virtual pharma models 46–47<br/><br/>See also research and development (R&D)<br/><br/>innovation challenge 5–9<br/><br/>innovation factors 8–9<br/><br/>innovation process, common themes 23–24<br/><br/>innovation product 5<br/><br/>innovative pharmaceutical pricing 86–87<br/><br/>institutional accountability 546–547<br/><br/>insurance technology 16<br/><br/>integrated delivery network (IDN) 11<br/><br/>integrative devices in mergers and acquisitions (M&As) 161–163<br/><br/>integrative mechanisms 524<br/><br/>integrative structures 8<br/><br/>internal co-promoting 139<br/><br/>investment exit options 357<br/><br/>IO (industrial organization) perspective 6–7, 130–131<br/><br/>IP (intellectual property)/patents issues 55, 103, 125, 132, 137, 198–199, 211, 287, 347, , 352, 360–361, 367–369, , 373–374, 516<br/><br/>IPO (initial public offering) 237, 238–239, 351, 352, 440–441<br/><br/>IRB (Institutional Review Board) 326<br/><br/>IT<br/><br/>See healthcare IT (information technology)<br/><br/>Japan<br/><br/>biotechnology industry 287–290<br/><br/>drug regulation 325–326<br/><br/>pharmaceutical industry 41<br/><br/>pharmaceutical pricing 50<br/><br/>stem cell research 310–311, 312<br/><br/>Jones, Fletcher 493<br/><br/>JPMA (Japan Pharmaceutical Manufacturers Association) 320<br/><br/>junk mail advertising 92<br/><br/>Kefauver Amendments (1962) 98<br/><br/>Köhler, George 212, 213<br/><br/>KOL (key opinion leader) physicians 90, 91<br/><br/>Koop, C. Everett 494<br/><br/>Lander, Eric 219<br/><br/>Lehman, Betsy 473<br/><br/>Lehman Brothers 370–371<br/><br/>licensing 154, 166, 167–169, 265, 315–316, 353, 356, 368–369,<br/><br/>Liu, Edison 372–373<br/><br/>local economies, technology sectors impact 21–23<br/><br/>long-term exploration 8<br/><br/>Longman, Roger 150<br/><br/>merger and acquisition (M&A) 5, 6, 9, 24–25, , 77, 126–129<br/><br/>absorption approach 164<br/><br/>biotechnology firms, trends in 124–130, 204–205<br/><br/>challenges and strategies 118<br/><br/>concentration ratios 437–439<br/><br/>consolidation 116<br/><br/>and converging business models 521<br/><br/>cost efficiencies and mergers 153–154<br/><br/>deal sizes 436–437<br/><br/>deal trends 439–440<br/><br/>deceleration 122<br/><br/>defense against acquisition 140–141<br/><br/>and disruptive change 145–146<br/><br/>diversification 166<br/><br/>earnings growth and pipeline problems 136–139<br/><br/>economies in marketing 154<br/><br/>economies in sales 154<br/><br/>execution of 159<br/><br/>and foreign pharmaceutical markets 141–142,<br/><br/>genomics companies 165<br/><br/>historical role of 117–118<br/><br/>as horizontal integration 157–158<br/><br/>in-licensing 154, 166, 167–169<br/><br/>and increased profit pressures 133–134<br/><br/>in industrial organization theory/research 130–132<br/><br/>industry concentration 158<br/><br/>informal networks 163<br/><br/>and infrastructure costs 134–136<br/><br/>and innovation 522<br/><br/>and integration 524<br/><br/>integrative devices 161–163<br/><br/>internal value chain integration 165<br/><br/>jumpstarting existing projects 166<br/><br/>mass-mergerers 138<br/><br/>medical devices industry 434–437,<br/><br/>merger activity, reasons for 170<br/><br/>multiple motivations 146<br/><br/>and new markets 132<br/><br/>offensive rationales 141–146<br/><br/>pharmaceutical firms 124–130, 132–146, 147–156, 521<br/><br/>post-merger cooperation 164<br/><br/>post-merger integration 164<br/><br/>preservation approach 164<br/><br/>proactive rationales 141–146<br/><br/>as productivity problem 156–159<br/><br/>project reductions 165–166<br/><br/>and research and development investment 150<br/><br/>Roche/Genentech relationship 227, 241, 269–270<br/><br/>and scale 150–152<br/><br/>and stock market activity 132<br/><br/>string of pearls strategy 164<br/><br/>symbiotic approach 164<br/><br/>McClellan, Mark 535<br/><br/>MacMillan, Ian 527<br/><br/>MAD (multiple ascending dose) study 56–57<br/><br/>Mallory, Steve 501<br/><br/>management of strategic alliances 528<br/><br/>managing the balancing act 528<br/><br/>managing knowledge 524<br/><br/>manufacturers<br/><br/>See producers<br/><br/>manufacturing management 62<br/><br/>market barriers and technology convergence 535–538<br/><br/>market dynamics and technology convergence 535–538<br/><br/>market share and scale 150–152<br/><br/>market structures, fragmented 521–522<br/><br/>marketing<br/><br/>across the value chain 87–88<br/><br/>biological targets 87<br/><br/>candidate selection 87<br/><br/>high-risk period 88<br/><br/>junk mail advertising 92<br/><br/>payer marketing organizations 94–95<br/><br/>pharmaceutical promotion 90–92<br/><br/>stakeholder complexities 88–89<br/><br/>mass-mergerers 138<br/><br/>MCO (managed care organization) 15, 172–173<br/><br/>me-too drugs 133<br/><br/>Medicaid 15, 89, 173, 411, 552<br/><br/>Medical Device Act (1976) 381<br/><br/>medical devices 26–27<br/><br/>atrial fibrillation 402<br/><br/>cardiac rhythm management sector sales 418<br/><br/>cardiovascular area 36, 383–384<br/><br/>channel efficiency 426<br/><br/>company operating margins 410–411<br/><br/>comparison with other industries 379–380<br/><br/>comparison with pharmaceutical industry 424–426<br/><br/>consumer/customer/payer separation 411–415<br/><br/>consumerism limitations 424–426<br/><br/>convergent technology 533<br/><br/>coronary artery bypass graft 396–397<br/><br/>costs 14–16, , 415–417<br/><br/>coverage ratio 408<br/><br/>decline in innovation 409<br/><br/>defibrillators 389–391, 392–393, 399–400, 415, 418<br/><br/>Department of Justice inquiry 377<br/><br/>in diabetes 402<br/><br/>direct selling 417–419<br/><br/>drug/device convergence 431–433<br/><br/>economics of clinical needs 415–417<br/><br/>education by sales reps 419–420<br/><br/>electronics 427–428<br/><br/>financing 440–441<br/><br/>firm clusters 21–22<br/><br/>franchises 419<br/><br/>growth drivers 395–400, 434<br/><br/>demographics 395<br/><br/>geographic reach 398–399<br/><br/>perennial products 398, 399<br/><br/>pricing 397<br/><br/>procedure penetration 396–397<br/><br/>recent 399–400<br/><br/>unmet clinical needs 395–396<br/><br/>growth projection rates 403–405<br/><br/>growth slowing consequences 405–409<br/><br/>corporate structural changes 407–408<br/><br/>segment shuffling 405–407<br/><br/>historical perspective 380–381<br/><br/>immunity to price pressures 414<br/><br/>industry analysis 382–391<br/><br/>industry consolidation 433–434<br/><br/>industry growth rates 391–395<br/><br/>industry as oligopoly 522<br/><br/>industry overview 376–378<br/><br/>industry revenues 379–380, 382–384<br/><br/>industry structure 384–386<br/><br/>information playback to manufacturer 420–421<br/><br/>innovation and commercialization challenges 518–519<br/><br/>interventional cardiology products 396–397<br/><br/>market size 382–384<br/><br/>materials sciences 428–431<br/><br/>mergers and acquisitions (M&As) 434–437,<br/><br/>misapplications/errors 380–381<br/><br/>neurological area 384<br/><br/>neuromodulation 402<br/><br/>neurovascular/stroke occlusion 401<br/><br/>orthopedic extremities 401<br/><br/>orthopedics sales 420<br/><br/>percutaneous coronary interventions 396–397, 401<br/><br/>physicians as customers 411, 421, 518–519<br/><br/>profits 423–424<br/><br/>research and development (R&D) 26–27, 422<br/><br/>robotic surgery 402<br/><br/>sales 421–424<br/><br/>target company valuation 434–435<br/><br/>taxation on 446<br/><br/>technology 426–433<br/><br/>US production/revenues 386–391<br/><br/>ventricle assist device (VAD) 401<br/><br/>world production/revenues 386–391<br/><br/>Medical Technologies Innovation Scorecard 22<br/><br/>Medicare 15, 89, 308, 411, 552<br/><br/>Medicare Modernization Act (2003) 16, 171<br/><br/>medicine supply 64<br/><br/>MEP (market exclusivity period) 136<br/><br/>merger activity, reasons for 170<br/><br/>microarrays 221–222<br/><br/>Milstein, Cesar 212, 213<br/><br/>mixed payment sources 551–552<br/><br/>molecular diagnostics companies 219<br/><br/>monoclonal antibodies 206, 208, 212–215<br/><br/>Moore, Gordon 456<br/><br/>Morgan Stanley financial report 261–262, 263<br/><br/>multinationals 103–105, 107, 108<br/><br/>multiple disciplines (silos) 8<br/><br/>multiple sclerosis 207–208<br/><br/>multiple treatment interference 147<br/><br/>Munos, Bernard 77<br/><br/>Myhrvold, Nathan 457<br/><br/>national economies, technology sectors impact 21–23<br/><br/>NCE (new chemical entity) 33–34, , 44, 55, 61,<br/><br/>NDAs (new drug application) 58, 59–60, , 85, 119, 314<br/><br/>negative innovation 529<br/><br/>neuroscience 36, 211<br/><br/>NEWbio (new biotech company) 38–39<br/><br/>NHE (national health expenditure) 172<br/><br/>NHI (National Health Insurance) (Japan) 50<br/><br/>NHIN (National Health Information Network) 462–463, 467–468<br/><br/>NICE (National Institute of Health and Clinical Excellence) (UK) 96, 121<br/><br/>Nicholas, Peter 388<br/><br/>Nicholson, David 262<br/><br/>NIH (National Institutes of Health) 37, 199–201, , 244, 311–312, 541<br/><br/>NME (new molecular entity) 24, 33, 44–45, , 77, 119, 149, 158, 260–261, 271<br/><br/>non-clinical development 60<br/><br/>NPfIT (National Programme for IT) 464–465<br/><br/>NRDO (no research, development only) model 225, 233–235<br/><br/>Nutt, Roy 493<br/><br/>Obama, President Barack 244, 307, 311–312, , 446, 452, 466<br/><br/>OCP (Office of Combination Products) 535<br/><br/>off-label promotion 99<br/><br/>on-label promotion 99<br/><br/>open source innovation/research 167, 169,<br/><br/>OPPAGA (Office of Program Policy Analysis and Government Accountability) (Florida) 95<br/><br/>organizational innovation perspective 8–9<br/><br/>organizational slack 8<br/><br/>Orphan Drug Act (1983) 316–318<br/><br/>OTC (over-the-counter) medications 33<br/><br/>OTC (over-the-counter) shift 426<br/><br/>out-licensing<br/><br/>See licensing<br/><br/>pacemakers 388<br/><br/>PACS (picture archiving communication and storage) 476<br/><br/>Pandemic and All-Hazard Preparedness Act 318–319<br/><br/>Parkinson, Jay 481–482<br/><br/>passive pharmaceuticals 20<br/><br/>patent cliff 98,<br/><br/>patents<br/><br/>See under intellectual property/patents<br/><br/>patient monitoring/management, remote 476, 480–481<br/><br/>Patient Protection and Affordable Care Act (2010) 307<br/><br/>patients, as consumers 411<br/><br/>payer activism 170–171<br/><br/>payer organizations 92–96<br/><br/>applications 486–490<br/><br/>claims management 483–488, ,<br/><br/>cost 93<br/><br/>cost-containment 172<br/><br/>and medical devices 411–415<br/><br/>payer integration 93<br/><br/>payer marketing organizations 94–95<br/><br/>payer size 92–93<br/><br/>structure 93<br/><br/>value chain alliances with pharmaceutical 174–175<br/><br/>PBM (pharmacy benefit management) 16, 133–134,<br/><br/>PBMs (pharmacy benefit managers) 89<br/><br/>PDL (preferred drug list) 95<br/><br/>period, definition of 356<br/><br/>Perot, H. Ross 492–494<br/><br/>PET (positron emission tomography) scanners 20<br/><br/>pharmaceutical industry 33–41<br/><br/>Asia 41, 46, 81<br/><br/>and biologics 129–130<br/><br/>biotechnology alliances 126–130, 204–205, 328, 352–353<br/><br/>biotechnology product issues 68–69<br/><br/>business challenges 72–73<br/><br/>business model 69–73<br/><br/>cash-flow model 70<br/><br/>cGMP (current good manufacturing practice) and compliance 62, 67<br/><br/>challenges to 111–112<br/><br/>comparison with medical devices industry 424–426<br/><br/>compound potency 65–66<br/><br/>conglomerate models 45<br/><br/>customer-focused culture 65<br/><br/>diversification 33, 44–45, , 122, 131–132<br/><br/>drug discovery 175<br/><br/>DTC (direct to consumer) advertising 16, 90, 100–101, , 425–426<br/><br/>efficiency in procurement 176–177<br/><br/>efficiency and scale/scope 152–155<br/><br/>example of 39–41<br/><br/>expansion into therapeutics 142–143<br/><br/>financing 37<br/><br/>forecast accuracy 65<br/><br/>generic drug companies 37–38<br/><br/>and government budgets 174<br/><br/>government development of 21–23<br/><br/>in-licensing 154, 166, 167–169<br/><br/>infrastructure costs 134–136<br/><br/>innovation<br/><br/>See innovation<br/><br/>and managed care organizations 172–173<br/><br/>manufacturing performance 64<br/><br/>mergers and acquisitions (M&As)<br/><br/>as productivity problem 156–159<br/><br/>trends in<br/><br/>See merger and acquisition (M&A)<br/><br/>in multiple technologies 515–516<br/><br/>OTC (over-the-counter) shift 426<br/><br/>outsourcing non-core functions 176–177<br/><br/>patent cliff 98,<br/><br/>process robustness 66<br/><br/>product markets 41–47<br/><br/>product safety withdrawals 137<br/><br/>profit structure 425–426<br/><br/>promotional techniques 90<br/><br/>quality culture 67–68<br/><br/>reach and frequency model 97–98<br/><br/>reliability of companies 64–65<br/><br/>revenue 517–518<br/><br/>revenue stream shocks 137<br/><br/>risk 46, 69–73<br/><br/>Russia 46<br/><br/>segments 41–47<br/><br/>and specialty pharmacy providers 173<br/><br/>system integration 64<br/><br/>transaction automation 176–177<br/><br/>value chain alliances with payers 174–175<br/><br/>West–East redeployment 78<br/><br/>See under drug; individual companies; innovation; research and development<br/><br/>pharmaceutical insurance coverage 49<br/><br/>pharmaceutical manufacturers<br/><br/>See pharmaceutical industry<br/><br/>pharmaceutical markets 35–36, 141–142<br/><br/>pharmaceutical pricing 47–50, , 86–87<br/><br/>pharmaceutical promotion 90–92<br/><br/>regulation 91–92, 97, 98–101<br/><br/>technological advances 101<br/><br/>pharmaceutical strategy<br/><br/>challenges to industry 117<br/><br/>drivers of 119–124<br/><br/>deconstruction of the pharmaceutical industry 121<br/><br/>decrease in research and development (R&D) productivity 119–121<br/><br/>diversification in business approach 122<br/><br/>diversification in capabilities 122–123<br/><br/>expansion in developing markets 123–124<br/><br/>synergistic combinations of businesses 123<br/><br/>pharmaceutical venture funds 245<br/><br/>pharmaceuticals 229–231<br/><br/>cancer trials 34–35<br/><br/>cost effectiveness 34–35<br/><br/>customer enthusiasm 48<br/><br/>definition 33<br/><br/>demand drivers 50–51<br/><br/>development 56–60<br/><br/>healthcare innovation environment 37<br/><br/>therapeutics 36<br/><br/>value of 34–35<br/><br/>pharmacogenomics 228<br/><br/>phases in research and development<br/><br/>See research and development<br/><br/>PHR (personal health record) 496–497<br/><br/>employer-sponsored 498–499<br/><br/>health communities 500–503<br/><br/>independent 499–500<br/><br/>insurer-sponsored 497–498<br/><br/>PhRMA (Pharmaceutical Research and Manufacturers of America) 99, 101, 320<br/><br/>physician organizations 96–97<br/><br/>Physician Payments Sunshine Act (2010) 11<br/><br/>physicians<br/><br/>access to IT 457<br/><br/>and CPOE (computerized physician order entry) 468–470, 472–473,<br/><br/>as customers 411, 421<br/><br/>and Kefauver Amendments (1962) 98<br/><br/>practice management 482–483<br/><br/>product control quotient 421<br/><br/>and research 176<br/><br/>shortages of 544–545, 552<br/><br/>PICC (peripherally inserted central catheter) 406<br/><br/>picks and shovels companies 365<br/><br/>pipeline NPV (net present value) 149–150<br/><br/>pipeline problems and earnings growth 136–139<br/><br/>PIPE (private investment in public equity) 239–241<br/><br/>Pirimal Life Sciences 45, 108, 142<br/><br/>platform technology business models 26, 228–231, 518<br/><br/>PoCs (proof-of-concept) declarations 119, 120, 165<br/><br/>Porter, Michael 6–7, 22<br/><br/>portfolio management and optimization 526–527<br/><br/>post-merger integration 164<br/><br/>PPACA (Patient Protection and Affordable Care Act 2010) 446<br/><br/>PPAR (peroxisome proliferator-activated receptor) 45–46<br/><br/>PPI (physician preference item) 12<br/><br/>PPO (preferred provider organization) 93<br/><br/>practice management 482–483<br/><br/>preregistration in research and development (R&D) 58–59<br/><br/>PricewaterhouseCoopers, Medical Technologies Innovation Scorecard 22<br/><br/>private placements 239<br/><br/>procedures costs 413<br/><br/>process of change 8<br/><br/>producer–provider alliances 16–17<br/><br/>producers 1–3, 17, 23–24,<br/><br/>product competition 555<br/><br/>product development cycles 23, 25<br/><br/>product innovation 5<br/><br/>product safety withdrawals 137<br/><br/>product sector margins 18–19<br/><br/>product sector prominence 17–18<br/><br/>productivity cliff 119<br/><br/>profitability and scale 150–152<br/><br/>programs of change 8<br/><br/>promotional techniques 90<br/><br/>Prospective Payment System (1983) 3<br/><br/>proteomic technology platform companies 363–366<br/><br/>proteomics 2, 219–220<br/><br/>providers 1–3<br/><br/>public sector insurance schemes 89<br/><br/>purchasers 1–3<br/><br/>pure innovation models 44–45<br/><br/>QALY (quality-adjusted life year) 416<br/><br/>Quintiles 46<br/><br/>research and development (R&D)<br/><br/>annual spending 260–261<br/><br/>in Asia 104, 110–111<br/><br/>biotechnology costs 354–355, 517–518<br/><br/>budgets 139<br/><br/>candidate selection 55<br/><br/>cash-flow model 70<br/><br/>declining productivity 121<br/><br/>development issues 56–60, 61, 69–73, 520<br/><br/>discovery stage 52, 69<br/><br/>dry well projects 69<br/><br/>economies of scale/scope in 143–145<br/><br/>genomics companies 165<br/><br/>governance 9<br/><br/>in-licensing 154, 166, 167–169<br/><br/>integrative devices in mergers and acquisitions (M&As) 161–163<br/><br/>intellectual property/patents 55<br/><br/>investigational new drug (IND) application 56<br/><br/>investment 5, 17, 45–46<br/><br/>and mergers and acquisitions (M&As) 150<br/><br/>per employee 21<br/><br/>lead generation 53–54<br/><br/>lead optimization 54–55<br/><br/>in medical device sector 26–27, 422<br/><br/>limited partnerships 241–243<br/><br/>merger and acquisition (M&A) problems 156–159<br/><br/>in multiple technologies 515–516<br/><br/>NME (new molecular entity) spending 271<br/><br/>non-clinical development 60<br/><br/>pharmaceutical/biotechnology alliances 126–130<br/><br/>phase I 53, 56–57, 61, 69, 176, 266, 315<br/><br/>phase II 53, 57, 61, 62, 69, 83–85, 87, 143–144, 149, 165, 167, 175<br/><br/>phase III 58, 61, 69, 83–85, 87, 91, 119, 137, 143–144, 149, 165, 167, 260, 274, 315, 364<br/><br/>phase IV 58, 60, 171<br/><br/>preclinical development 69<br/><br/>preregistration 58–59<br/><br/>productivity 125, 145<br/><br/>proof-of-concept studies 69<br/><br/>registration 59–60, 69, 85–86<br/><br/>research challenges 78–81<br/><br/>research density 148<br/><br/>research funding 37<br/><br/>risk 61–62, 69–73<br/><br/>Roche/Genentech relationship 135, 141, 269–270<br/><br/>and scale 143–145, 147–148, 148–150<br/><br/>and slowing growth 407, 408<br/><br/>spending as risk management 143–144<br/><br/>target identification 52<br/><br/>target validation 52–53<br/><br/>in value chain 51–62<br/><br/>RAC (Recombinant DNA Advisory Committee) 222<br/><br/>radiopharmaceutical tracers 20<br/><br/>RAND report 454–455<br/><br/>RBV (resource-based view) 7<br/><br/>RDD (rational drug design) 20, 220–221,<br/><br/>reach and frequency model 97–98<br/><br/>refusal to file letters 85<br/><br/>registration in research and development (R&D) 59–60<br/><br/>regulation restrictions 98–101<br/><br/>regulatory forces 6<br/><br/>related diversification 526<br/><br/>remote patient monitoring/management 476<br/><br/>revenue model and value capture 357<br/><br/>reverse innovation 529<br/><br/>RFID (radio frequency identification) 20<br/><br/>RHIO (regional health information organization) 462–463<br/><br/>rifle medicines 82<br/><br/>RIPCO (royalty-income [also research-intensive] pharmaceutical company) 225, 231–233, 236, 357, 517<br/><br/>risk participation 46<br/><br/>risk, and research and development (R&D) 61–62<br/><br/>RNAi (RNA interference) 222–223<br/><br/>ROI (return on investment) 143–144, 236<br/><br/>ROI (return on investment) calculus 553–555<br/><br/>royalties<br/><br/>See IP<br/><br/>SaaS (software as a service) 455<br/><br/>SAD (single ascending dose) study 56–57<br/><br/>Safe Medical Devices Act (1990) 535<br/><br/>sales channels 523<br/><br/>sales and scale 150–152<br/><br/>SAR (structure–activity relationship) 53–54<br/><br/>SBIR (Small Business Innovative Research) grants 243–244<br/><br/>scaffolds (protein structures) 214–215<br/><br/>scale 131, 143–145, 149, 150–155, , 523<br/><br/>scope, and efficiency 152–155<br/><br/>screening 53<br/><br/>SEC (Securities and Exchange Commission) 240<br/><br/>service company base, and innovation 46<br/><br/>SESAM-Vitale smartcard 463–464<br/><br/>SFDA (State Food and Drug Administration) (China) 104<br/><br/>SFE (sales force effectiveness) 101<br/><br/>SG&A (selling, general, and administrative) expenses 143<br/><br/>shareholder value maximization 8<br/><br/>Sharp, Phillip 232–233<br/><br/>sheep cloning 313–314<br/><br/>short-term efficiency 8<br/><br/>silos (multiple disciplines) 8<br/><br/>SinoFDA (Chinese Food and Drug Administration) 105<br/><br/>SKU (stock-keeping unit) 63<br/><br/>Smart House monitoring 478<br/><br/>SOC (standard of care) 82–83<br/><br/>sourcing ideas 8<br/><br/>specialized company proximity 22<br/><br/>speed to market 66<br/><br/>Starr, Paul 546<br/><br/>Steere, Bill 138<br/><br/>stem cell research 303–319,<br/><br/>stock market activity, and merger and acquisition (M&A) 132<br/><br/>stock price and scale 150–152<br/><br/>strategic alliances, management of 528<br/><br/>string of pearls strategy 164<br/><br/>STTR (Small Business Technology Transfer) 244<br/><br/>suppliers<br/><br/>care delivery implications 552–553<br/><br/>and downstream value chains 546<br/><br/>supply chain management 12<br/><br/>supply/demand disequilibria 64<br/><br/>surrogate endpoints 83<br/><br/>Swanson, Robert A. 196<br/><br/>SWORD (stock warrant offer for research and development) financing 241–243<br/><br/>synergies 131, 160–161<br/><br/>systems biology 20, 223–224, 362<br/><br/>Taylorism 157<br/><br/>TCM (traditional Chinese medicine) 102<br/><br/>TCT (transcatheter cardiovascular therapeutics) 416<br/><br/>technological imperative<br/><br/>in healthcare 3–5<br/><br/>non-appreciation of 10–11<br/><br/>technology convergence<br/><br/>across sectors 19–21, 531–538<br/><br/>and combination products 532–534<br/><br/>and differentiation 531<br/><br/>and diversification 531<br/><br/>in healthcare 531–534,<br/><br/>importance of 531<br/><br/>market barriers to 535–538<br/><br/>market dynamics and 535–538<br/><br/>and productivity 531<br/><br/>types of 533<br/><br/>and World Economic Forum (Davos) 532–534<br/><br/>technology development alliances 370–371,<br/><br/>technology platform companies 363–375,<br/><br/>technology platform model 26, 228–231<br/><br/>technology sectors, impact on economies 21–23<br/><br/>technology spending 3–4<br/><br/>technology transfer alliances 371–375, ,<br/><br/>technology zealots 327<br/><br/>therapeutic area alliances 368–369<br/><br/>therapeutic pharmaceutical pricing 48<br/><br/>therapeutically active devices 533<br/><br/>therapeutics 246<br/><br/>and biotechnology 25<br/><br/>Biotherapeutics and Bioinnovation Center (BBC) 130<br/><br/>economic importance of 36<br/><br/>neuroscience therapies 36<br/><br/>pharmaceutical industry expansion into 142–143<br/><br/>research and development (R&D) scale economics 149<br/><br/>TCT (transcatheter cardiovascular therapeutics) 416<br/><br/>therapies, in absence of standard of care 82–83<br/><br/>tool companies 218<br/><br/>toolbox companies 365<br/><br/>top-down strategy 8<br/><br/>total cost arguments 171<br/><br/>tPA (tissue plasminogen activator) 273, 307<br/><br/>TPS (Toyota Production System) 548<br/><br/>transgenic mice 213<br/><br/>Turner, Merv 262<br/><br/>Ubl, Steve 444–445<br/><br/>uHTS (ultra high-throughput screening) 80<br/><br/>United Kingdom, biotechnology industry 278–280<br/><br/>United States of America, pharmaceutical pricing 49<br/><br/>upstream supply costs 11–16,<br/><br/>value analysis committees 11–16,<br/><br/>value chain 7<br/><br/>alliances in 174–175<br/><br/>delivery product 554<br/><br/>disruptions to 546<br/><br/>and innovation 1–3<br/><br/>internal 24<br/><br/>and marketing 87–88<br/><br/>perspective on 7–8<br/><br/>positioning 357<br/><br/>VBP (value-based purchasing) 553,<br/><br/>VCs (venture capitalists) 38–39<br/><br/>Viehbacher, Chris 262<br/><br/>Vincent, James 232–233<br/><br/>virtual model 235<br/><br/>virtual pharma models, and innovation 46–47<br/><br/>virtual primary care 481–482<br/><br/>Wanless, Derek 464<br/><br/>Warner-Lambert 67, 137, 138, 139–140, , 154<br/><br/>Watson, James 109, 196–201,<br/><br/>Wears, Robert 472–473<br/><br/>Wharton School Healthcare Management courses 1–3, 9<br/><br/>Wilmut, Ian 313–314<br/><br/>Witty, Andrew 262<br/><br/>World Economic Forum (Davos), and technology convergence 532–534 |
| 520 ## - RESUMEN, ETC. | |
| Nota de sumario, etc. | El negocio de la innovación sanitaria y es un amplio análisis de las tendencias de negocios en el segmento de fabricación de la industria de la salud. Proporciona una visión completa e introducción a los sectores innovadores mejorando así la salud: productos farmacéuticos, biotecnología, tecnología de la plataforma, dispositivos médicos y tecnologías de la información. Para cada sector, el libro examina la base y las tendencias de la innovación científica, los modelos de negocio y de ingresos perseguidos para comercializar que la innovación, las limitaciones normativas en el que cada sector debe operar y los problemas crecientes que plantea el más pagadores activistas y consumidores. Los temas específicos incluyen la estructura del mercado y la competencia, la economía y la justificación del desarrollo de productos, precios, ventas y marketing, negociaciones de contratos con los compradores, alianzas frente a las fusiones, las estrategias de negocio y las perspectivas de crecimiento. Escrito por profesores de la Escuela Wharton y ejecutivos de la industria, el libro muestra por qué los sectores de la salud son una fuente muy importante de crecimiento de la economía de cualquier nación. |
| 650 #0 - ASIENTO SECUNDARIO DE MATERIA--TÉRMINO DE MATERIA | |
| Nombre de materia o nombre geográfico como elemento de entrada | CUIDADO MEDICO |
| Subdivisión general | INNOVACIONES TECNOLÓGICAS |
| 9 (RLIN) | 461 |
| 650 #0 - ASIENTO SECUNDARIO DE MATERIA--TÉRMINO DE MATERIA | |
| Nombre de materia o nombre geográfico como elemento de entrada | TECNOLOGÍA MEDICA |
| Subdivisión general | ASPECTOS ECONÓMICOS |
| 9 (RLIN) | 1845 |
| 650 #0 - ASIENTO SECUNDARIO DE MATERIA--TÉRMINO DE MATERIA | |
| Nombre de materia o nombre geográfico como elemento de entrada | PREVENCIÓN EN LOS NEGOCIOS |
| 9 (RLIN) | 1846 |
| 650 #0 - ASIENTO SECUNDARIO DE MATERIA--TÉRMINO DE MATERIA | |
| Nombre de materia o nombre geográfico como elemento de entrada | PREVENCIÓN ECONÓMICA |
| 9 (RLIN) | 1847 |
| 650 #0 - ASIENTO SECUNDARIO DE MATERIA--TÉRMINO DE MATERIA | |
| 9 (RLIN) | 1220 |
| Nombre de materia o nombre geográfico como elemento de entrada | BIOTECNOLOGÍA |
| Subdivisión general | ECONOMÍA |
| 700 1# - ENCABEZAMIENTO SECUNDARIO--NOMBRE PERSONAL | |
| Nombre de persona | Burns, Lawton R. |
| Término relacionador | edit |
| 9 (RLIN) | 1848 |
| 942 ## - ELEMENTOS KOHA | |
| Fuente de clasificación o esquema de ordenación en estanterías | |
| Koha tipo de item | LIBRO - MATERIAL GENERAL |
| Disponibilidad | Mostrar en OPAC | Fuente de clasificación o esquema | Tipo de Descarte | Estado | Código de colección | Localización permanente | Localización actual | Localización en estanterías | Fecha adquisición | Proveedor | Forma de Adq | Precio normal de compra | Datos del ítem (Volumen, Tomo) | Número de Inventario | Préstamos totales | Renovaciones totales | Signatura completa | Código de barras | Fecha última consulta | Fecha último préstamo | Número de ejemplar | Coste, precio de reemplazo | Propiedades de Préstamo KOHA | Fecha de Descarte | Programa Académico |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Préstamo Normal | Colección / Fondo / Acervo / Resguardo | Biblioteca Jorge Álvarez Lleras | Biblioteca Jorge Álvarez Lleras | Fondo general | 2015-04-13 | Libreria Medica Celsus-860091403-OC20545 | Compra | 180000.00 | Ej. 1 | BIB0001279 | 3 | 2 | 610.28 B979 | 023888 | 2023-07-19 | 2023-01-17 | 1 | 180000.00 | LIBRO - MATERIAL GENERAL | 2015-04-13 | Maestría en Ingeniería Industrial |
AK. 45 No. 205 - 59, Autopista Norte.
PBX: +60(1) 668 3600 - Bogotá.